In the present study, we investigated whether treatment with GBCK25 facilitated the recovery of hemodynamic parameters, left ventricle systolic pressure, left ventricular developed pressure, and electrocardiographic changes. GBCK25 significantly prevented the decrease in hemodynamic parameters and ameliorated the electrocardiographic abnormality. These results indicate that GBCK25 has distinct cardioprotective effects in rat heart.
electrocardiogram (ECG) parameters were studied. The developed maximal rates of contraction (þdP/dt max ) and relaxation (ÀdP/ dt max ) were recorded after 120 min reperfusion. Both þdP/dt max and ÀdP/dt max were studied as indices of cardiac contractility. All statistics were calculated using SigmaPlot for Windows version 12.0 (Systat Software, Inc., USA). For all studies, significance was statistically considered at p < 0.05.
The effect of GBCK25 on the hemodynamics was assessed by measuring cardiac function including coronary flow, aortic flow, and cardiac output. These parameters were substantially decreased by I/R induction to an average of 66.37 AE 4.92%, 69.51 AE 4.65%, and 65.04 AE 3.27% compared to an N/C group as 100%, respectively. However, pretreatment with GBCK25 (200 mg/kg and 400 mg/kg) increased coronary flow, aortic flow, and cardiac output to an average of 72.68 AE 4.79%, 73.24 AE 5.02%, and 72.86 AE 6.39%, respectively, using 200 mg/kg GBCK25, and to an average of 82.42 AE 5.31%, 81.37 AE 4.17%, and 82.43 AE 5.21%, respectively, using 400 mg/kg GBCK25 (Fig. 2 (60 min), 81.9 AE 3.6% (90 min), and 82.7 AE 3.7% (120 min) compared to the N/C group as 100%, respectively ( Fig. 3 ). Likewise, I/R induction resulted in a significant fall in average þdP/dt max values to 52.9 AE 3.75% for 120 min, whereas pretreatment with GBCK25 significantly increased the average þdP/dt max values to 63.69 AE 4.74% in 200 mg/kg GBCK25, and 84.63 AE 4.55% in 400 mg/ kg GBCK25 for 120 min, respectively ( Fig. 4A ). Under the same conditions, the average ÀdP/dt max values were 62.75 AE 3.63% compared to the N/C group as 100% in the I/R group. However, GBCK25 significantly increased edP/dt max values to an average of 69.65 AE 3.52% in 200 mg/kg GBCK25, and 78.47 AE 4.71% in 400 mg/ kg GBCK25 for 120 min, respectively ( Fig. 4B ). As seen in Figs. 2e4, there was no difference between hemodynamics such as LVSP and AE dP/dt max between the N/C and the GBCK25 groups. These results suggest that GBCK25 itself did not influence cardiac hemodynamic function in the experiments.
In the ECG study, the normal group showed a normal ECG. No significant differences on conduction intervals for the GBCK25 group and the N/C group were observed as seen in Fig. 5 . However, when studying ECG parameters after 30 min ischemia and 120 min reperfusion, the QRS interval tended to be significantly delayed compared to the N/C group (Fig. 5 ). In I/R control, an average of QRS values was 138.24 AE 5.22% for 120 min compared to the N/C group (an average N/C value as 100). As shown in Fig. 5 , animals in the I/R group also produced the pathological R amplitude, showing transmural cardiac infarction. However, the QRS interval significantly shortened in the 200 mg/kg and 400 mg/kg GBCK25-treated groups compared to the I/R group for 120 min I/R induction.
Average values of QRS intervals were 130.71 AE 4.95% for the 200 mg/kg GBCK25-treated group and 122.16 AE 4.73% for the 400 mg/kg GBCK25-treated group compared to the I/R control group for 120 min (Fig. 5 ). As shown in Fig. 5B , the 400 mg/kg GBCK25-treated group was more effective than the 200 mg/kg GBCK25-treated group (p < 0.5, p < 0.01). The results indicated that treatment with 400 mg/kg GBCK25 is more effective than with 200 mg/kg GBCK25 in the preservation of atrioventricular conduction. In addition, in the GBCK25 control group, QT interval alteration was similar to the N/C group, as seen in Fig. 5C . Moreover, I/R induction produced significant delayed QT interval compared to N/C animals. In the I/R control group, an average QT value is 136.37 AE 5.22 % for 120 min when compared to the N/C group (an average N/C value as 100%). For the 200 mg/kg and 400 mg/kg GBCK25-treated groups, QT interval significantly shortened compared to the I/R group. Namely, the average values of QT interval for 120 min were 129.18 AE 4.52% for the 200 mg/kg GBCK25treated group and 123.51 AE 3.73% for the 400 mg/kg GBCK25treated group. As shown in Fig. 5 , the GBCK15 control group had no significant effectiveness in the QT interval study for total 180 min I/R periods (p > 0.5). The results indicated that treatment with GBCK25 can be effective in the preservation of repolarization. Also, it is known that heart rate interval is studied with the R to R wave (RR) [6] .
In the present study, a normal RR interval was obtained, similar to the N/C group. However, in the I/R group, the RR interval tended to be significantly delayed compared to the N/C group. Compared to the N/C group (N/C value as 100%), the I/R group had an RR interval of 123.66 AE 3.71% for 120 min reperfusion. These values were changed when 200 mg/kg and 400 mg/kg GBCK25 were used as shown in Fig. 5D . Namely, the RR intervals for 200 mg/kg and 400 mg/kg GBCK25-treated groups were 118.22 AE 2.95% and 110.61 AE 2.89%, respectively. These data were significantly shorter than the I/R control for 120 min reperfusion.
These results indicated that treatment with 200 mg/kg and 400 mg/kg GBCK25 can be effective in the preservation of heart rate in rats (Fig. 5D) . Therefore, the present study provides a preliminary possibility for the application of GBCK25. However, further studies need to be carried out to give assurance that these results can be used for humans. In the point of the safety and efficacy of GBCK25, prospective further studies should be considered. 
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